Holen Sie sich die Stockscreener-App
5.42
8.84%
0.44
Handel nachbörslich:
5.42
Schlusskurs vom Vortag:
$4.98
Offen:
$5.01
24-Stunden-Volumen:
710.92K
Relative Volume:
6.86
Marktkapitalisierung:
$308.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-66.86M
KGV:
-4.5167
EPS:
-1.2
Netto-Cashflow:
$-58.82M
1W Leistung:
+24.60%
1M Leistung:
+38.27%
6M Leistung:
+36.52%
1J Leistung:
+22.90%
1-Tages-Spanne:
$5.01
$5.48
1-Wochen-Bereich:
$3.95
$5.48
52-Wochen-Spanne:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Vergleichen Sie DSGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
5.42 | 274.49M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Will Design Therapeutics Inc. rebound enough to break even2025 Macro Impact & Free Safe Entry Trade Signal Reports - Newser
Will Design Therapeutics Inc. continue its uptrend2025 Retail Activity & AI Forecasted Stock Moves - Newser
Will Design Therapeutics Inc. stock recover after recent drop2025 Historical Comparison & Expert Verified Stock Movement Alerts - Newser
Is Design Therapeutics Inc. stock ready for a breakoutWeekly Profit Recap & Weekly Watchlist of Top Performers - Newser
Price action breakdown for Design Therapeutics Inc.Portfolio Return Summary & High Conviction Investment Ideas - Newser
Price action breakdown for Design Therapeutics Inc. [July 2025 Final Week]Fast Entry High Yield Tips - Newser
Can momentum traders help lift Design Therapeutics Inc.Earnings Overview Summary & Daily Profit Maximizing Tips - Newser
Technical analysis overview for Design Therapeutics Inc. stockWeekly Gains Report & Verified Swing Trading Watchlist - Newser
Using Bollinger Bands to evaluate Design Therapeutics Inc.Dollar Strength & Real-Time Buy Signal Alerts - Newser
News impact scoring models applied to Design Therapeutics Inc.Trade Analysis Summary & Technical Confirmation Trade Alerts - Newser
Is Design Therapeutics Inc. stock a growth or value playTechnical Setup and Return Forecast Engine - Newser
Published on: 2025-08-13 11:59:52 - 선데이타임즈
Design Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers Say5-Year Price Trend Summary and Analysis - Newser
How to manage a losing position in Rapport Therapeutics Inc.Strategy Builder for Growth Focused Traders - Newser
KORU Medical Systems And 2 Other Penny Stocks To Watch For Growth - simplywall.st
Advanced analytics toolkit walkthrough for Design Therapeutics Inc.Swing Trade Picks with High Potential - Newser
Heatmap analysis for Design Therapeutics Inc. and competitorsFree High Yield Stocks With Buy Confirmation - Newser
What momentum shifts mean for Design Therapeutics Inc.Risk Aware Trading Ideas with Alert Levels - Newser
How sentiment analysis helps forecast Design Therapeutics Inc.Free Low Drawdown Real Time Trading Tips - Newser
Trend analysis for Design Therapeutics Inc. this weekNeural Network Based Equity Prediction System - Newser
Long term hold vs stop loss in Design Therapeutics Inc.Insider Strategy for High Conviction Picks - Newser
How to escape a deep drawdown in Design Therapeutics Inc.Smart Risk Entry Zone Technical Analysis - Newser
What high frequency data says about Design Therapeutics Inc.AI Screener for Daily Stock Forecast - Newser
Design Therapeutics, Inc. shares rise 10.05% intraday after 4DMT reported positive 60-week results from 4D-150 SPECTRA clinical trial in DME. - AInvest
What makes Design Therapeutics Inc. stock attractive to long term investorsPrice Movement and Market Sentiment Analysis - Newser
What MACD and RSI say about Design Therapeutics Inc.Free Daily Chart Pattern Stock Forecast - Newser
Risk vs reward if holding onto Design Therapeutics Inc.Buy Candidate Summary Based on Fundamentals - Newser
What technical models suggest about Design Therapeutics Inc.’s comebackFree Smart Trend Trading with Weekly Signals - Newser
What makes Design Therapeutics Inc. stock price move sharplyReal Chart Based Opportunity Identification - Newser
Machine Learning Models Forecast Design Therapeutics Inc. UptickEntry Plan for Oversold Reversal Stocks Released - metal.it
Backtesting results for Design Therapeutics Inc. trading strategiesFree AI Screening for Swing Trade Picks - Newser
Using flow based indicators on Design Therapeutics Inc.Technical Reversal Setup with Risk Limits - Newser
Will breakout in Design Therapeutics Inc. lead to full recoveryHistorical Stock Summary and ROI Review - Newser
Has Design Therapeutics Inc. found a price floorFree ROI Boosting Trade Opportunity Calendar - Newser
Design Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Design Therapeutics Advances GeneTAC Programs Amid FDA Hold, Reports Q2 Financial Results - AInvest
Design Therapeutics reports Q2 EPS (34c), consensus (33c) - TipRanks
Design Therapeutics Q2 net loss misses expectations - MarketScreener
Design Therapeutics Advances GeneTAC Programs Amid FDA Hold - TipRanks
Design Therapeutics Clinical Trial Shows Promising PK Data for Friedreich Ataxia Drug | DSGN Stock News - Stock Titan
Market reaction to Design Therapeutics Inc.’s recent newsPredictive Model for Intraday Swing Forecast - Newser
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):